“Unhappy” BMS To ImClone: Erbitux, Follow-on Still Ours
This article was originally published in The Pink Sheet Daily
Executive Summary
After the rejected buyout offer, rights to compounds won't be modified.
You may also be interested in...
Amylin, Lilly Partnership Tested By Lilly GLP-1 Project
Byetta relationship is “the best it has ever been,” Amylin says, but impact of Lilly’s competitive research will need to be negotiated.
Icahn To Cornelius: “I Don’t Understand”
ImClone chairman scolds Bristol-Myers Squibb CEO in latest correspondence.
Amylin, Lilly Partnership Tested By Lilly GLP-1 Project
Byetta relationship is “the best it has ever been,” Amylin says, but impact of Lilly’s competitive research will need to be negotiated.